.svg){kind=small}
Driving innovation
in clinical research
.png)
At the forefront of drug evolution
Leading the way in First-in-Human studies with a variety of patient populations.
Take your asset from First-in-Human to Proof of Concept in under one year with our specialist services.
Take your asset from First-in-Human to Proof of Concept in under one year with our specialist services.
Thorough QT Studies
.svg)
Take your asset from FIH to POC in under one year using our specialist services.
-min.jpg)
We are Richmond Pharmacology.
We are committed to advancing science and driving innovations in drug development.
We reduce drug development timelines using knowledge and expertise accumulated from over 500 clinical trials.
We reduce drug development timelines using knowledge and expertise accumulated from over 500 clinical trials.
Centre of excellence.
Richmond Pharmacology is a centre for excellence for First-In-Human and early phase clinical studies. We reduce drug development timelines using our Adaptive Protocols and efficient Patient Recruitment.
Our sponsors are granted fast international marketing approvals due to our inclusive study design which fulfils the data requirements of global regulators.
Our sponsors are granted fast international marketing approvals due to our inclusive study design which fulfils the data requirements of global regulators.
Work with us
We work with leading genetic engineering organisations, top 10 pharma companies and dynamic biotechs to assess the safety and efficacy of new therapeutics.
By working with us, you will gain a research partner who can expedite your study start up, enable fast decisions and reduce your drug development timelines.
-min.jpg)
.jpg)
Latest news
Futureproofing early phase clinical research for the next generation of investigators.
March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read moreDirector of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.
January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read moreEvents
13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event
